Navigation Links
Now hear this: Stanford researchers identify forerunners of inner-ear cells that enable hearing
Date:2/26/2013

colleagues identified a class of cells called tympanic border cells that can give rise to hair cells and the cells that support them during a phase of cochlear maturation right after birth.

"Until now, these cells have had no clear function," said Cheng. "We used several techniques to define their behavior in cell culture dishes, as well as in mice. I hope these findings will lead to new areas of research to better understand how our ears develop and perhaps new ways to stimulate the regeneration of sensory cells in the cochlea."

Cheng recently received a grant from the California Institute for Regenerative Medicine to study the limited regeneration of the same sensory hair cells that occur in a different region of the inner ear called the vestibular system, which helps us balance. Lessons learned there may also translate into aid for patients with hearing loss.

Although regeneration of sensory hair cells does not happen naturally, recent research has suggested that the mammalian ear may harbor a sub-population of presumably inactive progenitor cells. The research team led by Cheng and Nusse used a strain of laboratory mice that allowed the scientists to track the activation of a cell-signaling pathway driven by a protein called Wnt. The Wnt pathway has previously been shown to be involved in many developmental functions, and it drives the renewal and proliferation of many types of stem cells.

"We wanted to investigate the Wnt pathway because of its tremendous influence in the development and regeneration of many other organs," said Cheng.

The researchers found that tympanic border cells, or TBCs, which form a thin layer under the sensory epithelium, are actively dividing in mice during the first three weeks after birth (the time corresponding to about the first trimester of human development, during which the ability to hear is established) and give rise to at least a subset of sensory and non-sensory cells in the ear.
'/>"/>

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Hear This: 3-D Printing Creates Lifelike Artificial Ears
2. Immune cells engineered in lab to resist HIV infection, Stanford study shows
3. Optogenetics illuminates pathways of motivation through brain, Stanford study shows
4. Stanford/Yale study gives insight into subtle genomic differences among our own cells
5. Mechanism found for destruction of key allergy-inducing complexes, Stanford researchers say
6. Stanford bioengineer Karl Deisseroth wins NIH Transformative Research Award
7. MBL and Stanford scientists receive 2012 Lasker Award for Basic Medical Research
8. Little evidence of health benefits from organic foods, Stanford study finds
9. Mathematics or memory? Stanford study charts collision course in brain
10. Stanford/Intel study details power of new chip to diagnose disease, analyze protein interactions
11. Community health centers compare well with private practices, Stanford researcher finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Florida Hospital and MOSI officially announced a transformational ... to come and make a difference in the Tampa Bay ... check to provide the support needed to keep the science ... transform the IMAX Dome Theatre from film to a state-of-the-art ... Dome Theatre in the state of Florida, and it is ...
(Date:7/25/2014)... -- The human brain can preserve oxygen to protect ... finds. Although dehydration significantly reduces blood flow ... the brain compensates by increasing the amount of oxygen ... helped us understand a lot more about how the ... study first author Steven Trangmar, a researcher at Brunel ...
(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... revealed that 39 percent of all children in the survey ... , The survey looked at 2,505 children during the years of ... four years of age. The final result was that about ... care. Many of these children were from lower-income families and were ...
(Date:7/25/2014)... 25, 2014 A new study of participants ... which are published today in Cancer , found evidence ... 74 who had an abnormal finding on a lung cancer ... of life than did those who were screened and found ... surprise to the researchers. “We expected that participants with an ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5
... http://www.cryocath.com , Toronto Stock Exchange Symbol: CYT, ... leader in cryotherapy products to treat cardiac,arrhythmias, today announced ... Selected Third Quarter Financial and Operational Highlights: ... $9.2 million or a 12.0% increase over ...
... NANJING, China, Aug. 5 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: ... branded generic,pharmaceuticals and manufacturer of the patented anti-cancer biotech,product ... the,quarter ended June 30, 2008., Highlights ... for the second quarter, representing ...
... Mass., Aug. 5 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ... third quarter ended June 30, 2008. The,Company will host ... am,eastern time (details follow below)., The Company reported ... $19.0 million or $0.25 per share for the quarter ...
... IRVINE, Calif., Aug. 5 SectorWatch.biz announces the,availability ... release of,articles and message boards relative to the ... aforementioned equities and the,opportunity for investors to respond ... can view MarketStats by visiting: http://www.SectorWatch.biz ,-a ...
... Goodison goes for gold and aims to give back to Mercy Ships ... ... European Laser Champion and one of Britain,s greatest medal hopes at the ... seagoing charity Mercy Ships which provides free medical care to the people ...
... age management practice, announced the opening of Cenegenics Indiana. ... leader is launching over 2008-2009. The new Cenegenics Indiana ... The center,s established protocols and personalized programs for healthy ... Minutes, 20/20, Nightline and GQ. , ...
Cached Medicine News:Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 12Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 13Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 12Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 2Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 3Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 4Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 5Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 6Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 7Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 8Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 9Health News:SectorWatch.biz Issues MarketStats for Healthy and Organic Companies ORGC, DF, WFMI, LWAY, COIN, and TOF 2Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 2Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 3Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 4
(Date:7/24/2014)... 24, 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... the development and commercialization of innovative therapies for the ... PDUFA date for Zalviso remains July 27, 2014.  ... online stating the Food and Drug Administration (FDA) had ... been no notification to the company from the FDA ...
(Date:7/24/2014)... 24, 2014  Restore Health, a leading personalized ... announced that it is now offering pharmacogenetics testing ... individual based upon their particular genetic makeup. Comprehensive ... interaction between a patient,s genetics and their entire ... to provide this new service to healthcare providers ...
(Date:7/24/2014)... Inc. (NASDAQ: UPI ), a medical device ... products to treat voiding dysfunctions, today reported financial ... 30, 2014.  Global revenue for the ... to $4.1 million, as compared to $3.4 million ... Total revenue for the fiscal first quarter of ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... 4, 2010 Reportlinker.com announces that ... available in its catalogue: ... - Metastatic gastrointestinal cancers represent a ... lack of approved drugs ...
... 4, 2010 AccuVein LLC, the developer of the ... it had been awarded the maximum grant amount from ... grant program supports projects that show significant potential to ... the long-term growth of health care costs. ...
Cached Medicine Technology:Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 2Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 3Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 4Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 5Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 6Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 7Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 8Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 9Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 10Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 11Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 12Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 13Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 14Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 15Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 16Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic Gastrointestinal Cancers Represent a Significant Commercial Opportunity Due to a Lack of Approved Drugs 17AccuVein Receives Grant for its Award Winning AV300 Vein Illumination System 2
New! Visually superior, micrometer handle, single foot plate, blade extends to 3.0 mm....
... new approach to practice management, built to address ... healthcare market. OPIE was created by practicing O&P ... in this field, so it thinks the way ... than anything else available. If you believe there ...
... a comprehensive pocket-sized reference to ... on the evaluation and management of diseases ... Updated annually. The complete content is available ... for Pocket PC- and Palm-based PDAs are ...
... The Medical Imaging Consultant, PDA Edition ... fellows who may order diagnostic imaging studies. ... device to extensive information that will help ... based on symptoms, and which studies will ...
Medicine Products: